|
Market Closed -
Nasdaq
04:00:00 30/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 56.49 USD | -1.40% |
|
+41.22% | +83.41% |
| 10-29 | Deutsche Bank raises price target for Genmab to DKK 4,000 (3,500), reiterates buy - BN | FW |
| 10-29 | AlphaValue/Baader Europe Downgrades Genmab to Sell | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 64.38B | |||||
| 56.16B | |||||
| 54.16B | |||||
| 45.33B | |||||
| 42.25B |
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
- Charts Genmab A/S
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
